Autologous hematopoietic cell transplantation for chronic myelogenous leukemia

Hematology/Oncology Clinics of North America

Volumn 18, Issue 3, 2004, Pages 715-732

  Bhatia, Ravi ^a   McGlave, Philip B ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RISK; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; EX VIVO STUDY; FOLLOW UP; HEMATOPOIESIS; HUMAN; IN VIVO STUDY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 3242763754     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.03.006     Document Type: Review

References (111)

1. Coulombel L., Kalousek D.K., Eaves C.J., Gupta C.M., Eaves A.C. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med. 308:1983;1493-1498
2. Verfaillie C.M., Miller W.J., Boylan K., McGlave P.B. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR expression. Blood. 79:1992;1003-1010
3. Leemhuis T., Leibowitz D., Cox G., Silver R., Srour E.F., Tricot G., et al. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood. 81:1993;801-807
4. Delforge M., Boogaerts M.A., McGlave P.B., Verfaillie C.M. BCR/ABL- CD34(+)HLA-DR-progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Blood. 93:1999;284-292
5. Goto T., Nishikori M., Arlin Z., Gee T., Kempin S., Burchenal J., et al. Growth characteristics of leukemic and normal hematopoietic cells in Ph′ + chronic myelogenous leukemia and effects of intensive treatment. Blood. 59:1982;793-808
6. Carella A.M., Dejana A., Lerma E., Podesta M., Benvenuto F., Chimirri F., et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol. 95:1996;127-130
7. Wang J.C., Lapidot T., Cashman J.D., Doedens M., Addy L., Sutherland D.R., et al. High level engraftment of NOD/SClD mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 91:1998;2406-2414
8. O'Brien S.G., Deininger M.W. lmatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol. 40:2003;26-30
9. Haines M.E., Goldman J.M., Worsley A.M., McCarthy D.M., Wyatt S.E., Dowding C., et al. Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients. Br J Haematol. 58:1984;711-721
10. Sirard C., Lapidot T., Vormoor J., Cashman J.D., Doedens M., Murdoch B., et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood. 87:1996;1539-1548
11. Reiffers J., Trouette R., Marit G., Montastruc M., Faberes C., Cony-Makhoul P., et al. Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br J Haematol. 77:1991;339-345
12. Reiffers J., Goldman J., Meloni G., Cahn J.Y., Faberes C., Apperley J. Autologous transplantation in chronic myelogenous leukemia: European results: Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant. 14(Suppl 3):1994;S51-S54
13. Khouri I.F., Kantarjian H.M., Talpaz M., Giralt S., Rios M.O., Hester J.P., et al. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant. 17:1996;775-779
14. Mughal T., Hoyle C., Goldman J.M. Autografting for patients with chronic myeloid leukemia:-the Hammersmith experience. Stem Cells. 11(Suppl 3):1993;20-22
15. Pigneux A., Faberes C., Boiron J.M., Mahon F.X., Cony-Makhoul P., Agape P., et al. Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience. Bone Marrow Transplant. 24:1999;265-270
16. Barnett M.J., Eaves C.J., Phillips G.L., Gascoyne R.D., Hogge D.E., Horsman D.E., et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study [comments]. Blood. 84:1994;724-732
17. Coutinho L.H., Chang J., Brereton M.L., Morgenstern G.R., Scarffe J.H., Harrison C.J., et al. Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study. Bone Marrow Transplant. 19:1997;969-976
18. McGlave P.B., Arthur D., Miller W.J., Lasky L., Kersey J. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant. 6:1990;115-120
19. Carlo-Stella C., Mangoni L., Almici C., Caramatti C., Cottafavi L., Dotti G.P., et al. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant. 14:1994;425-432
20. Szczylik C., Skorski T., Nicolaides N.C., Manzella L., Malaguarnera L., Venturelli D., et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 253:1991;562-565
21. de Fabritiis P., Amadori S., Calabretta B., Mandelli F. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant. 12:1993;261-265
22. de Fabritiis P., Petti M.C., Montefusco E., De Propris M.S., Sala R., Bellucci R., et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood. 91:1998;3156-3162
23. Luger S.M., O'Brien S.G., Ratajczak J., Ratajczak M.Z., Mick R., Stadtmauer E.A., et al. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood. 99:2002;1150-1158
24. Ratajczak M.Z., Kant J.A., Luger S.M., Hijiya N., Zhang J., Zon G., et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA. 89:1992;11823-11827
25. Bedi A., Griffin C.A., Barber J.P., Vala M.S., Hawkins A.L., Sharkis S.J., et al. Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Res. 54:1994;5535-5538
26. Gladstone D.E., Bedi A., Miller C.B., Noga S.J., Griffin C.A., Piantadosi S., et al. Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia. Biol Blood Marrow Transplant. 5:1999;394-399
27. Roy D.C., Bioileau J., Laplante J., Busque L., Fish D., Kassis J., et al. Phase I study of autologous progenitor cell transplantation (PCT) with a photodynamic approach for patients with chronic myelogenous leukemia (CML). Blood. 96:2001;583A
28. Simonsson B., Oberg G., Bjoreman M., Bjorkholm M., Carneskog J., Gahrton G., et al. Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group. Bone Marrow Transplant. 17(Suppl 3):1996;S63-S64
29. Carella A.M., Cunningham I., Lerma E., Dejana A., Benvenuto F., Podesta M., et al. Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol. 15:1997;1575-1582
30. Carella A.M. Autografting with non-clonal mobilized hematopoietic progenitor cells in CML. Leukemia. 14:2000;954-955
31. Carella A.M., Lerma E., Corsetti M.T., Dejana A., Basta P., Vassallo F., et al. Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood. 93:1999;1534-1539
32. Carella A.M., Chimirri F., Podesta M., Pitto A., Piaggio G., Dejana A., et al. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant. 17:1996;201-205
33. Chalmers E.A., Franklin I.M., Kelsey S.M., Newland A.C., Clark R.E., Sproul A.M., et al. Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol. 96:1997;627-634
34. Sureda A., Petit J., Brunet S., Boque C., Aventin A., Martino R., et al. Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis. Bone Marrow Transplant. 24:1999;1285-1290
35. Singer I.O., Franklin I.M., Clark R.E., Chalmers E.A., Kelsey S.M., Newland A.C., et al. Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells. Br J Haematol. 102:1998;1359-1362
36. Morton J., Mollee P., Taylor K., Grigg A., Durrant S., Moore D., et al. Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Leuk Res. 23:1999;177-183
37. Waller C.F., Heinzinger M., Rosenstiel A., Lange W. Mobilization and transplantation of Philadelphia chromosome-negative peripheral blood progenitor cells in patients with CML. Br J Haematol. 103:1998;227-234
38. Fischer T., Neubauer A., Mohm J., Huhn D., Busemann C., Link H., et al. Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML. Bone Marrow Transplant. 21:1998;1029-1036
39. Fischer T., Neubauer A., Mohm J., Huhn D., Busemann C., Link H., et al. Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied. Ann Hematol. 77:1998;21-26
40. Janssen J.J., van Rijn R.S., van der Holt B., Schuurhuis G.J., Vellenga E., Verhoef G.E., et al. Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests. Bone Marrow Transplant. 25:2000;1147-1155
41. Pratt G., Johnson R.J., Rawstron A.C., Barnard D.L., Morgan G.J., Smith G.M. Autologous stem cell transplantation in chronic myeloid leukaemia using Philadelphia chromosome negative blood progenitors mobilised with hydroxyurea and G-CSF. Bone Marrow Transplant. 21:1998;455-460
42. Verfaillie C.M., Bhatia R., Steinbuch M., DeFor T., Hirsch B., Miller J.S., et al. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood. 92:1998;1820-1831
43. Hughes T.P., Grigg A., Szer J., Ho J., Ma D., Dale B.M., et al. Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. Br J Haematol. 96:1997;635-640
44. Talpaz M., Kantarjian H., Liang J., Calvert L., Hamer J., Tibbits P., et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 85:1995;3257-3263
45. Archimbaud E., Michallet M., Philip I., Charrin C., Clapisson G., Belhabri A., et al. Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol. 99:1997;678-684
46. Reiffers J., Taylor K., Gluckman E., Gorin N.C., Mahon F.X., Miclea J.M., et al. Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant alpha-interferon. Br J Haematol. 102:1998;639-646
47. Meloni G., Russo D., Baccarani M., Testoni N., Martinelli G., Fanin R., et al. A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica. 84:1999;707-715
48. Hernandez-Boluda J.C., Carreras E., Cervantes F., Marin P., Arellano-Rodrigo E., Rovira M., et al. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Haematologica. 87:2002;17-22
49. Boiron J.M., Cahn J.Y., Meloni G., Carlo-Stella C., Bandini G., Reman O., et al. Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias. Bone Marrow Transplant. 24:1999;259-264
50. Rowe J.M., Rapoport A.P., Ryan D.H., Nilsson B.I., Duerst R.E., Packman C.H., et al. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex. Bone Marrow Transplant. 24:1999;1057-1063
51. Carlo-Stella C., Regazzi E., Andrizzi C., Savoldo B., Garau D., Montefusco E., et al. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Haematologica. 82:1997;291-296
52. McGlave P.B., De Fabritiis P., Deisseroth A., Goldman J., Barnett M., Reiffers J., et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet. 343:1994;1486-1488
53. Bhatia R., Verfaillie C.M., Miller J.S., McGlave P.B. Autologous transplantation therapy for chronic myelogenous leukemia. Blood. 89:1997;2623-2634
54. Druker B., Tamura S., Buchdunger E., Ohni S., Segal G., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566
55. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037
56. Talpaz M., Silver R.T., Druker B., Paquette R., Goldman J.M., Reese S.F., et al. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myelogenous leukemia in accelerated phase. Blood. 96:2000;469A
57. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al. lmatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:2002;3530-3539
58. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652
59. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 349:2003;1423-1432
60. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99:2002;1928-1937
61. Bhatia R., Slovak M.L., McDonald T., Gray R., Holtz M., Snyder D.S., et al. PBSC collected from patients in complete cytogenetic remission on imatinib mesylate treatment are Ph- by standard criteria but are contaminated with BCF/ABL+ progenitor cells. Blood. 100:2002;109A
62. Hui C.H., Goh K.Y., White D., Branford S., Grigg A., Seymour J.F., et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia. 17:2003;821-828
63. Maziarz R.T., Chauncey T.R., Capdeville R., Druker B.J., Seelig F. Growth factor mobilization of CD34+ PBSC in CML patients treated with imatinib (STI571). Blood. 98:2001;738A
64. Kebriaei P., Sher D., Carlson K., Litwiller H., Odenike O., Smith S., et al. Feasibility of autologous stem cell collection and kinetics of minimal residual disease (MRD) in CML patients (pts) treated with imatinib mesylate (IM). Proc Am Soc Clin Oncol. 222:2003;. [Abstract 3359]
65. Bhatia R., McGlave P.B., Dewald G.W., Blazar B.R., Verfaillie C.M. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood. 85:1995;3636-3645
66. Deisseroth A.B., Zu Z., Claxton D., Hanania E.G., Fu S., Ellerson D., et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 83:1994;3068-3076
67. Snyder D.S., Wu Y., McMahon R., Yu L., Rossi J.J., Forman S.J. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Biol Blood Marrow Transplant. 3:1997;179-186
68. Clark R.E. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia. 14:2000;347-355
69. Zhao R.C., McIvor R.S., Griffin J.D., Verfaillie C.M. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood. 90:1997;4687-4698
70. Scherr M., Battmer K., Winkler T., Heidenreich O., Ganser A., Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 101:2003;1566-1569
71. Wohlbold L., van der Kuip H., Miething C., Vornlocher H.P., Knabbe C., Duyster J., et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood. 102:2003;2236-2239
72. Wisniewski D., Lambek C.L., Liu C., Strife A., Veach D.R., Nagar B., et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62:2002;4244-4255
73. La Rosee P., Johnson K., O'Dwyer M.E., Druker B.J. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 30:2002;729-737
74. Klejman A., Rushen L., Morrione A., Slupianek A., Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 21:2002;5868-5876
75. Bhatia R., Munthe H.A., Williams A.D., Zhang F., Forman S.J., Slovak M.L. Increased sensitivity of chronic myelogenous leukemia primitive hematopoietic progenitors to growth factor induced cell division and maturation. Exp Hematol. 12:2000;1401-1412
76. Petzer A.L., Eaves C.J., Barnett M.J., Eaves A.C. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood. 90:1997;64-69
77. Gale R.P., Horowitz M.M., Ash R.C., Champlin R.E., Goldman J.M., Rimm A.A., et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 120:1994;646-652
78. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 75:1990;555-562
79. Klingemann H.G., Neerunjun J., Schwulera U., Ziltener H.J. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production. Leukemia. 7:1993;1389-1393
80. Verma U.N., Bagg A., Brown E., Mazumder A. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant. 13:1994;115-123
81. Cervantes F., Pierson B.A., McGlave P.B., Verfaillie C.M., Miller J.S. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood. 87:1996;2476-2485
82. Hoyle C., Bangs C.D., Chang P., Kamel O., Mehta B., Negrin R.S. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 92:1998;3318-3327
83. Miller J.S. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 29:2001;1157-1168
84. Cathcart K., Pinilla-lbarz J., Korontsvit T., Schwartz J., Zakhaleva V., Papadopoulus E.B., et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 103:2004;1037-1042
85. Cheever M.A., Chen W., Disis M.L., Takahashi M., Peace D.J. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. Ann N Y Acad Sci. 690:1993;101-112
86. ten Bosch G.J., Toornvliet A.C., Friede T., Melief C.J., Leeksma O.C. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia. 9:1995;1344-1348
87. Greco G., Fruci D., Accapezzato D., Barnaba V., Nisini R., Alimena G., et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia. 10:1996;693-699
88. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S.Y., Sette A., et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 87:1996;3587-3592
89. Clark R.E., Dodi I.A., Hill S.C., Lill J.R., Aubert G., Macintyre A.R., et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 98:2001;2887-2893
90. Pinilla-lbarz J., Cathcart K., Korontsvit T., Soignet S., Bocchia M., Caggiano J., et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 95:2000;1781-1787
91. Cheever M.A., Disis M.L., Bernhard H., Gralow J.R., Hand S.L., Huseby E.S., et al. Immunity to oncogenic proteins. lmmunol Rev. 145:1995;33-59
92. Bellantuono I., Gao L., Parry S., Marley S., Dazzi F., Apperley J., et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 100:2002;3835-3837
93. Gao L., Bellantuono I., Elsasser A., Marley S.B., Gordon M.Y., Goldman J.M., et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WTI. Blood. 95:2000;2198-2203
94. Yang X.F., Wu C.J., McLaughlin S., Chillemi A., Wang K.S., Canning C., et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 98:2001;7492-7497
95. Molldrem J.J., Clave E., Jiang Y.Z., Mavroudis D., Raptis A., Hensel N., et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 90:1997;2529-2534
96. Molldrem J.J., Lee P.P., Wang C., Champlin R.E., Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59:1999;2675-2681
97. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 6:2000;1018-1023
98. Smit W.M., Rijnbeek M., van Bergen C.A., de Paus R.A., Vervenne H.A., van de Keur M., et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum lmmunol. 53:1997;216-223
99. Heinzinger M., Waller C.F., von den Berg A., Rosenstiel A., Lange W. Generation of dendritic cells from patients with chronic myelogenous leukemia. Ann Hematol. 78:1999;181-186
100. Choudhury A., Gajewski J.L., Liang J.C., Popat U., Claxton D.F., Kliche K.O., et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 89:1997;1133-1142
101. Zheng C., Pisa P., Stromberg O., Blennow E., Hansson M. Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia. Med Oncol. 17:2000;270-278
102. Dong R., Cwynarski K., Entwistle A., Marelli-Berg F., Dazzi F., Simpson E., et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood. 101:2003;3560-3567
103. Zeis M., Siegel S., Wagner A., Schmitz M., Marget M., Kuhl-Burmeister R., et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol. 170:2003;5391-5397
104. Gabriele L., Borghi P., Rozera C., Sestili P., Andreotti M., Guarini A., et al. IFN-{alpha} promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood. 103:2004;980-987
105. Stam A.G., Santegoets S.J., Westers T.M., Sombroek C.C., Janssen J.J., Tillman B.W., et al. CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br J Cancer. 89:2003;1162-1165
106. Fujii S., Shimizu K., Fujimoto K., Kiyokawa T., Shimomura T., Kinoshita M., et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res. 90:1999;1117-1129
107. Takahashi T., Tanaka Y., Nieda M., Azuma T., Chiba S., Juji T., et al. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res. 27:2003;795-802
108. Ossenkoppele G.J., Stam A.G., Westers T.M., de Gruijl T.D., Janssen J.J., van de Loosdrecht A.A., et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia. 17:2003;1424-1426
109. Sun J.Y., Krouse R.S., Forman S.J., Senitzer D., Sniecinski I., Chatterjee S., et al. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res. 62:2002;3175-3183
110. Kantarjian H.M., O'Brien S., Cortes J.E., Giralt S.A., Rios M.B., Shan J., et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 100:2002;1590-1595
111. La Rosee P., Johnson K., Corbin A.S., Stoffregen E.P., Moseson E.M., Willis S., et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl positive cell lines. Blood. 103:2004;208-215